

Remibrutinib treatment has no clinical impact on mean blood cell counts in patients with chronic spontaneous urticaria: Pooled safety analysis from REMIX-1 and REMIX-2 studies

G. Mosnaim, H. Windom, G. Xinghua, M. Metz, S. Saini, A. Fukunaga, A. Burciu, S. Huang, K. Lheritier, H. Zouater, S. Haemmerle, A.G-Arnau

Please click [HERE](#) to subscribe to news alerts of the Novartis Urticaria Knowledge Center and to receive an email notification once the publication is available

Or use this [LINK](#) to access the publication once it has been presented at the congress

AAAAI/WAO Joint Congress 2025, American Academy of Allergy, Asthma & Immunology (AAAAI) and World Allergy Organization (WAO), February 28 – March 3, 2025